APHP - Hopital Saint Louis

Paris 9001

2 studies enrolling now · 12 studies all time

What they study most

Acute GVHD, Acute Myelogenous Leukemia, Acute-graft-versus-host Disease, Adenovirus Infection, Adult Disease, Adult T Cell Leukemia/Lymphoma, Advanced Melanoma, Advanced Solid Tumor, Advanced or Metastatic NRAS-mutant Melanoma, B-cell Lymphoma, BK Virus Infection, Cutaneous Melanoma

Studies at this site

• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — Recruiting now
• A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) — Recruiting now
• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) — Running, not enrolling
• Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) — Paused
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) — Running, not enrolling
• A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Running, not enrolling
• A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). — Completed
• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
• A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) — Stopped early
• HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy — Running, not enrolling
• Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant — Stopped early
• Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) — Stopped early